We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
+22.13%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$230M
AUM Growth
+$16.2M
Cap. Flow
+$20.4M
Cap. Flow %
8.88%
Top 10 Hldgs %
89.88%
Holding
24
New
7
Increased
1
Reduced
8
Closed
4

Top Buys

Rank Stock Value
1
AKAO
Achaogen Inc
AKAO
+$17.9M
2
BPMC
Blueprint Medicines
BPMC
+$9.04M
3
IRTC icon
iRhythm Holdings
IRTC
+$4.48M
4
EDIT icon
Editas Medicine
EDIT
+$4.17M
5
ACRS icon
Aclaris Therapeutics
ACRS
+$3.97M

Top Sells

Rank Stock Value
1
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$6.96M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$6.89M
3
AERI
Aerie Pharmaceuticals
AERI
+$3.76M
4
WVE icon
Wave Life Sciences
WVE
+$1.67M
5
LPCN icon
Lipocine
LPCN
+$1.35M

Sector Composition

Rank Sector Weight
1 Healthcare 50.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
1
DELISTED
Aerie Pharmaceuticals
AERI
$60.5M 26.29%
1,598,452
-99,432
-6% -$3.76M
AKAO
2
DELISTED
Achaogen Inc
AKAO
$34M 14.76%
+2,607,984
New +$17.9M
ALDR
3
DELISTED
Alder Biopharmaceuticals
ALDR
$33.9M 14.72%
1,628,328
+42,645
+3% +$1.11M
AIMT
4
DELISTED
Aimmune Therapeutics
AIMT
$18.5M 8.03%
903,890
-31,130
-3% -$636K
WVE icon
5
Wave Life Sciences
WVE
$1.13B
$17.7M 7.68%
676,128
-51,368
-7% -$1.67M
NSTG
6
DELISTED
NanoString Technologies, Inc.
NSTG
$9.77M 4.25%
438,133
-47,467
-10% -$1.02M
NTLA icon
7
Intellia Therapeutics
NTLA
$1.49B
$9.22M 4.01%
703,563
-60,125
-8% -$903K
BPMC
8
DELISTED
Blueprint Medicines
BPMC
$8.41M 3.66%
+300,000
New +$9.04M
PTGX icon
9
Protagonist Therapeutics
PTGX
$8.71B
$7.62M 3.31%
346,281
– –
EPZM
10
DELISTED
Epizyme, Inc
EPZM
$7.32M 3.18%
605,239
-6,538
-1% -$68.2K
IRTC icon
11
iRhythm Holdings
IRTC
$3.86B
$4.99M 2.17%
+166,210
New +$4.48M
EDIT icon
12
Editas Medicine
EDIT
$396M
$4.46M 1.94%
+274,910
New +$4.17M
ACRS icon
13
Aclaris Therapeutics
ACRS
$737M
$4.23M 1.84%
+155,767
New +$3.97M
ASND icon
14
Ascendis Pharma A/S
ASND
$16.3B
$3.64M 1.58%
+180,000
New +$3.6M
LRMR icon
15
Larimar Therapeutics
LRMR
$390M
$1.49M 0.65%
39,117
-5,674
-13% -$230K
AKTX
16
Akari Therapeutics
AKTX
$14.4M
$1.39M 0.6%
246
– –
BOLD
17
DELISTED
Audentes Therapeutics, Inc
BOLD
$1.22M 0.53%
66,553
– –
GBT
18
DELISTED
Global Blood Therapeutics, Inc.
GBT
$919K 0.4%
63,627
-391,963
-86% -$6.89M
XLRN
19
DELISTED
Acceleron Pharma
XLRN
$507K 0.22%
+19,886
New +$630K
OREX
20
DELISTED
Orexigen Therapeutics, Inc.
OREX
$442K 0.19%
254,257
– –
LPCN icon
21
Lipocine
LPCN
$17.6M
– –
-17,802
Closed -$1.35M
SYRS
22
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-6,000
Closed -$832K
MNTA
23
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-595,513
Closed -$6.96M
BDSI
24
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-47,158
Closed -$127K

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q4 2016 Portfolio in Review

As of Q4 2016, Foresite Capital Management III held 24 positions worth $230M, up 7.6% from $214M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Foresite Capital Management III deployed $20.4M of net new capital in Q4 2016, opening 7 new positions and adding to 1 existing holding. Its largest new stake was Achaogen Inc: 2,607,984 shares worth $34M.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 63% a quarter earlier.

On the sell side, the largest reduction was Global Blood Therapeutics, Inc., an estimated $6.89M trimmed.

  • Foresite Capital Management III's largest Q4 2016 buy was Achaogen Inc: 2,607,984 shares worth $34M.
  • Foresite Capital Management III added most to Alder Biopharmaceuticals in Q4 2016, an estimated $1.11M increase.
  • Foresite Capital Management III's biggest Q4 2016 reduction was Global Blood Therapeutics, Inc., cutting an estimated $6.89M.
  • Foresite Capital Management III fully exited Momenta Pharmaceuticals, Inc. in Q4 2016, selling an estimated $6.96M.
  • Foresite Capital Management III's ten largest holdings make up 90% of its $230M portfolio in Q4 2016.
  • Foresite Capital Management III opened 7 new positions and closed 4 in Q4 2016.
  • Foresite Capital Management III's portfolio value rose 7.6% quarter-over-quarter to $230M.

Based on Foresite Capital Management III's 13F filing for Q4 2016, filed 10 Feb 2017.